Viking Therapeutics, Inc. (VKTX)
US — Healthcare Sector
Automate Your Wheel Strategy on VKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VKTX
- Rev/Share 0.0
- Book/Share 5.6056
- PB 6.1475
- Debt/Equity 0.0002
- CurrentRatio 9.3338
- ROIC -0.6154
- MktCap 3981990840.0
- FreeCF/Share -2.4445
- PFCF -14.2885
- PE -10.9238
- Debt/Assets 0.0002
- DivYield 0
- ROE -0.4804
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VKTX | Canaccord Genuity | -- | Buy | -- | $106 | Oct. 29, 2025 |
| Initiation | VKTX | Cantor Fitzgerald | -- | Overweight | -- | $104 | April 29, 2025 |
| Initiation | VKTX | Goldman | -- | Neutral | -- | $30 | April 8, 2025 |
| Initiation | VKTX | Scotiabank | -- | Sector Outperform | -- | $102 | Feb. 13, 2025 |
| Initiation | VKTX | Citigroup | -- | Neutral | -- | $38 | Feb. 7, 2025 |
| Initiation | VKTX | JP Morgan | -- | Overweight | -- | $80 | Sept. 11, 2024 |
News
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
VKTX
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
ABT,
PFE,
VKTX
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Viking Therapeutics, Inc. (VKTX)
- IPO Date 2015-04-28
- Website https://www.vikingtherapeutics.com
- Industry Biotechnology
- CEO Brian Lian
- Employees 45
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.